Viewing Study NCT05512780



Ignite Creation Date: 2024-05-06 @ 6:01 PM
Last Modification Date: 2024-10-26 @ 2:40 PM
Study NCT ID: NCT05512780
Status: UNKNOWN
Last Update Posted: 2022-08-23
First Post: 2022-08-22

Brief Title: Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positiveHER2-negative Breast Cancer
Sponsor: Hebei Medical University Fourth Hospital
Organization: Hebei Medical University Fourth Hospital

Study Overview

Official Title: An Exploratory Clinical Study of CDK46 Inhibitor Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positiveHER2-negative Breast Cancer
Status: UNKNOWN
Status Verified Date: 2022-08
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a single-arm open-label exploratory clinical study
Detailed Description: This is a single-arm open-label exploratory clinical study initiated by the investigator to evaluate the objective response rate ORR efficacy and safety of Dalpiciclib combined with letrozole in the neoadjuvant treatment of stage Ⅱ-Ⅲ HRHER2- breast cancer

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None